RecruitingPhase 3NCT07743580

A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease

A Phase 3 Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Secutrelvir in Participants With COVID-19 Who Are at High Risk for Progression to Severe Disease

Sponsor

Shionogi

Enrollment

2,000 participants

Start Date

Aug 31, 2026

Study Type

INTERVENTIONAL

Conditions

SARS CoV-2

Summary

The primary purpose of this study is to evaluate the efficacy and safety of secutrelvir in symptomatic nonhospitalized adult and adolescent participants with COVID-19 who are at high risk for progression to severe disease.

Eligibility

Min Age: 12 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called Secutrelvir for people with sars cov-2. The study is currently recruiting participants at 27 locations. People eligible for this study include aged 12 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSecutrelvir

Secutrelvir will be administered orally as a tablet.

DRUGPlacebo

Placebo will be administered orally as a tablet.

Locations(34)

Hope Clinical Trials - 3970 W Flagler St.

Coral Gables, Florida, United States

Continental Clinical Research, LLC

Miami, Florida, United States

Reed Medical Research

Miami, Florida, United States

Kendall South Medical Center Inc.

Miami, Florida, United States

Global Clinical Professionals

St. Petersburg, Florida, United States

New Tampa Health

Tampa, Florida, United States

Research Bay, Inc.

Tampa, Florida, United States

Hometown Urgent Care and Research

Cincinnati, Ohio, United States

Medical Center Unimed EOOD

Sevlievo, Gabrovo, Bulgaria

Medichi Sofia - Medical Center OOD

Sofia, Sofia, Bulgaria

MCpulmo-2018 Ltd

Haskovo, Bulgaria

Medical Center Medconsult Pleven - Lovech Branch

Lovech, Bulgaria

Medical Center Medconsult Pleven OOD

Pleven, Bulgaria

Abe Shun Naika Clinic

Kasugai-Shi, Aiti, Japan

Chiba Aoba Municipal Hospital

Chiba, Chiba, Japan

Japan Community Health Care Organization Nihonmatsu Hospital

Nihommatsu, Fukushima, Japan

Kikuchi Clinic

Maebashi, Gunma, Japan

Tsuchiura Beryl Clinic

Takasaki-shi, Gunma, Japan

Toda Internal Medicine & Neurology

Akashi-Shi, Hyôgo, Japan

Terada Clinic Respiratory Medicine and General Practice

Himeji-shi, Hyôgo, Japan

Kamezawa Clinic

Tsuchiura-Shi, Ibaraki, Japan

Sato Clinic

Kawasaki-shi, Kanagawa, Japan

Shinjo Terasu Clinic

Kawasaki-shi, Kanagawa, Japan

Shibasaki Internal Medicine and Pediatrics Clinic

Sendai, Miyagi, Japan

Matsuo Kenko Clinic

Sendai, Miyagi, Japan

Sugiura Clinic

Kawaguchi-shi, Saitama, Japan

Tokyo Center Clinic

Chuo-Ku, Tokyo, Japan

Nishikasai ekimae Clinic

Edogawa-ku, Tokyo, Japan

Morishita Ekimae Clinic

Koto-ku, Tokyo, Japan

Shizuka Medicine Clinic

Musashino, Tokyo, Japan

Yotsuya Naika

Shibuya-Ku, Tokyo, Japan

Medical Corporation Shirayurikai Swing Nozaki Clinic

Shinjuku-Ku, Tokyo, Japan

Okura ENT Clinic

Toshima-ku, Tokyo, Japan

Tomita Internal Medicine Clinic

Fukuoka, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07743580

Related Trials

Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease

NCT072244901 location

Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)

NCT066843793 locations

A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

NCT065852416 locations

Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19

NCT074165391 location

COVID-19 - Study of the Kinetics of the Immune Response During the Intensive Care Unit Stay in Adult Patients Infected With SARS-CoV-2: Multicentric Non Interventional Study

NCT043924018 locations